Vascular RiskVITALNCT07122427
Aging of the Vascular Wall
An observational study of Vascular Risk and Aging Disorder, run by Centre Hospitalier Universitaire de Saint Etienne at 1 site in France.
Trial summary
Demographic aging is predicted to be one of the most significant social changes of the 21st century. Aging is a slow, multifactorial process that progressively impacts the integrity of cells, tissues, and organs. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Vascular Risk, Aging Disorder
- What is being tested?
- Graft collection
- Type of treatment
- Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- 17 Jul 2025to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients requiring coronary artery bypass grafting (CABG).
Who may be able to join
- Major patients requiring coronary artery bypass grafting (CABG).
Who cannot join
- Hypertension, diabetes, systemic inflammatory disease.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Saint-Etienne
Saint-Etienne, France, 42055
Anne-Claire DUCHEZ, PhD, (0)477421423 ext. +33, anne-claire.duchez@efs.sante.fr
Anne-Claire DUCHEZ, PhD
About this study
Demographic aging is predicted to be one of the most significant social changes of the 21st century. Aging is a slow, multifactorial process that progressively impacts the integrity of cells, tissues, and organs. This decline in function increases the risk of numerous diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases (CVD). CVD, the leading global cause of death, becomes more prevalent with age. Aging contributes to endothelial dysfunction, vessel stiffness, thickening, and impaired platelet function. These changes disrupt hemostatic processes and increase the risk of cardiovascular complications. Despite preventive strategies CVD remain a major public health challenge. Cellular aging, or senescence, affects all cell types, particularly endothelial cells and platelets. However, little research has compared the aging rates of different blood vessel types, such as arteries and veins. Given their distinct compositions and developmental origins, it is likely that their aging processes differ at molecular, cellular, and physiological levels.
- Conditions
- Vascular Risk, Aging Disorder
- Being tested
- Graft collection
- Keywords
- Cardiovascular diseases, Aging, Eendothelial dysfunction
- Medical subject headings
- Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Graft collectionProcedure or surgery
Sampling of superior venous and arterial grafts (internal mammary artery, great saphenous vein) after coronary artery bypass surgery.
| Study group | Role | What they receive |
|---|---|---|
| Youngs | Patients aged 18 to 30 requiring coronary artery bypass grafting (CABG). Receives: Procedure: Graft collection | |
| Middle-aged | Patients aged 30 to 60 requiring coronary artery bypass grafting (CABG). Receives: Procedure: Graft collection | |
| Elderly | Patients aged 60 and more requiring coronary artery bypass grafting (CABG). Receives: Procedure: Graft collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Biomarkers of ageing
Detection of innovative biomarkers of ageing by microscope analysis.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2025
- Study start17 Jul 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vascular RiskStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de Saint EtienneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Salvatore CAMPISI, MD, Principal investigator, Centre Hospitalier Universitaire de Saint Etienne
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07122427
- Sponsor's protocol ID
- IRBN502025/CHUSTE
- Acronym
- VITAL
- Status last verified
- Aug 2025
- First submitted
- 7 Aug 2025
- Last updated
- 20 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Aging of the Vascular Wall
- ClinicalTrials.gov ID
- NCT07122427
- Acronym / sponsor ID
- VITAL / IRBN502025/CHUSTE
- Conditions
- Vascular Risk, Aging Disorder
- Keywords
- Cardiovascular diseases, Aging, Eendothelial dysfunction
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de Saint EtienneUniversity, hospital or other
- Study start
- 17 Jul 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 14 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Demographic aging is predicted to be one of the most significant social changes of the 21st century. Aging is a slow, multifactorial process that progressively impacts the integrity of cells, tissues, and organs. This decline in function increases the risk of numerous diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases (CVD). CVD, the leading global cause of death, becomes more prevalent with age. Aging contributes to endothelial dysfunction, vessel stiffness, thickening, and impaired platelet function. These changes disrupt hemostatic processes and increase the risk of cardiovascular complications. Despite preventive strategies CVD remain a major public health challenge. Cellular aging, or senescence, affects all cell types, particularly endothelial cells and platelets. However, little research has compared the aging rates of different blood vessel types, such as arteries and veins. Given their distinct compositions and developmental origins, it is likely that their aging processes differ at molecular, cellular, and physiological levels.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Youngs | – | Procedure: Graft collectionPatients aged 18 to 30 requiring coronary artery bypass grafting (CABG). |
| Middle-aged | – | Procedure: Graft collectionPatients aged 30 to 60 requiring coronary artery bypass grafting (CABG). |
| Elderly | – | Procedure: Graft collectionPatients aged 60 and more requiring coronary artery bypass grafting (CABG). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients requiring coronary artery bypass grafting (CABG).
Key inclusion criteria (1 listed)
- Major patients requiring coronary artery bypass grafting (CABG).
Key exclusion criteria (1 listed)
- Hypertension, diabetes, systemic inflammatory disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Graft collectionSampling of superior venous and arterial grafts (internal mammary artery, great saphenous vein) after coronary artery bypass surgery. | Procedure or surgery | Elderly, Middle-aged, Youngs |
Primary outcome
Biomarkers of ageing
Time frame: Day 1
Detection of innovative biomarkers of ageing by microscope analysis.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Vascular Risk
Active, not recruitingObservational study
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia
Active, not recruitingPhase 2
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Multiple Myeloma
RecruitingObservational study
China HEalthy Aging and Dementia Study (HEAD)
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Active, not recruitingPhase 2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma
RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
Atherosclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Salvatore CAMPISI, MD principal investigator
Centre Hospitalier Universitaire de Saint Etienne
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Vascular Risk and Aging Disorder, run by Centre Hospitalier Universitaire de Saint Etienne at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anne-Claire DUCHEZ, PhD ((0)477421423 ext. +33, anne-claire.duchez@efs.sante.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Biomarkers of ageing (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2025.